Developer docs
API playgroundTry for free, no card

Search company profiles

JDRF T1D Fund

Full company profile

uuid0005lye

Namestring
JDRF T1D Fund
Legal namestring
The T1D Fund: A Breakthrough T1D Venture, LLC
Websiteurl
t1dfund.org
Company typeenum
Private
Founded yearint
2016
Descriptiontext

The T1D Fund (legally "The T1D Fund: A Breakthrough T1D Venture, LLC") is a Boston-based venture impact fund founded in 2016 as the first scaled venture vehicle exclusively devoted to accelerating treatments, prevention, and cures for Type 1 Diabetes. It operates as a wholly owned not-for-profit subsidiary of Breakthrough T1D (formerly JDRF), a 501(c)(3) organization, and is governed by an independent Investment Committee. The fund makes equity investments in early-stage biotech companies pursuing disease-modifying therapies and curative approaches, co-investing alongside venture capital firms and biopharmaceutical companies across autoimmune and regeneration, cell replacement, and metabolic control modalities. Notable portfolio companies include Sana Biotechnology, Century Therapeutics, Aspect Biosystems, Sonoma Biotherapeutics, DiogenX, Zucara Therapeutics, and Zag Bio, among 25+ companies invested since inception.

The fund's business model is impact-driven and evergreen: capital is sourced through charitable contributions from donors, family foundations, and Breakthrough T1D itself (including a recently announced $150+ million capital raise campaign), and 100% of investment returns are reinvested into new T1D investments rather than distributed. With $250M+ in assets under management, the fund deploys catalytic capital to de-risk programs and create a flywheel effect that attracts additional investors to the T1D space, while providing portfolio companies with access to Breakthrough T1D's research, clinical, regulatory, and medical affairs networks. The fund is based at 50 Milk Street, 16th Floor, Boston, MA 02109, and is supported by an 11-50 person team led by CEO Elizabeth Mily alongside Managing Directors Sylvia Tobé and Lucio Iannone, with recent senior additions including Head of Strategy & Industry Engagement Daniel McNamara and strategic consultant Teresa Foy, Ph.D.

Short descriptiontext

The T1D Fund is a Boston-based venture philanthropy fund (founded 2016) that makes equity investments in early-stage biotech companies developing disease-modifying therapies and cures for Type 1 Diabetes, co-investing with VCs and biopharma as a wholly owned subsidiary of Breakthrough T1D.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture philanthropy fund, biotech impact investing, healthcare venture capital, therapeutics equity investment, clinical-stage biotech funding
Industry2 codes
PRIMARYFSANAJAN
SDG / Thematic Sustainable Investment Funds
Financial & Insurance/Private Equity & Venture Capital/Impact / ESG & Sustainable Investment Funds
SECONDARYBPAGALAA
Impact Investing & Social Finance (Funds, CDFIs, Microfinance)
Business & Public Services/Nonprofit, NGO & Social Services/Social Enterprises & Impact Organizations
NAICS code1 code
  • Open-End Investment Funds525910
SIC code1 code
  • Investment Advice6282
Product category
Venture Philanthropy / Impact Investment Fund
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Impact Investment Returns
TypeTransaction Fee
Description

As an evergreen impact investment fund, the T1D Fund makes equity investments in biotech companies pursuing T1D treatments and cures. All returns from investments are reinvested into new investments, creating a continuous cycle of progress that fuels foundational research and accelerates program development.

t1dfund.org
2Charitable Contributions
TypeSubscription Recurring
Description

Funded through charitable contributions from donors and from Breakthrough T1D itself. As a wholly owned subsidiary of Breakthrough T1D, a 501(c)(3) organization, all donor contributions raised for the Fund are recorded as charitable donations where donors receive tax benefits.

t1dfund.org
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

The JDRF T1D Fund is a venture impact fund that makes equity investments in early- and clinical-stage biotech companies developing treatments and cures for Type 1 Diabetes. The fund, a wholly owned subsidiary of Breakthrough T1D (formerly JDRF), manages $250M+ in committed capital across 20+ active portfolio companies and reinvests 100% of investment returns back into the T1D mission. It also operates a co-investment platform that enables accredited investors and biopharma partners to participate alongside the fund in T1D financings.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

The T1D Fund operates as a single venture impact fund platform focused on catalyzing treatments, prevention, and cures for type 1 diabetes. The fund makes equity investments in early-stage biotech companies through its co-investment platform, supporting companies across immunotherapy, beta cell therapy, metabolic control, and improving lives approaches. With $250M+ in assets under management and 20+ active portfolio companies (including Aera Therapeutics, Adaxion Therapeutics, AltruBio, Aspect Biosystems, Bigfoot Biomedical, Biolinq, Century Therapeutics, COUR Pharmaceuticals, DiogenX, GentiBio, Immunocore, Inversago Pharma, Jaguar Gene Therapy, Kriya Therapeutics, Mozart Therapeutics, Sana Biotechnology, Semma Therapeutics, Sonoma Biotherapeutics, ZagBio, Zucara Therapeutics, and others), the fund provides investment capital alongside strategic support, leveraging the network and expertise of Breakthrough T1D. All returns are reinvested into the fund to fuel continued progress in T1D therapeutic development.

Product and service2 records
1JDRF T1D Fund Venture Impact Fund
CategoryVenture Philanthropy / Impact Investment Fund
Description

Equity investment fund making venture-stage investments into early- and clinical-stage biotech companies developing disease-modifying, curative, prevention, beta cell replacement, and diagnostic therapies for Type 1 Diabetes. Targeted at founders and management teams of T1D-focused biotech companies.

2T1D Co-Investment Platform
CategoryCo-Investment Platform
Description

Syndication platform that allows accredited investors, family offices, VC firms, and biopharma strategic partners to participate alongside the JDRF T1D Fund in portfolio company financings through a donor-advised fund (ImpactAssets) structure with preferred-return economics.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

The T1D Fund is a wholly owned subsidiary of Breakthrough T1D (formerly JDRF), the leading global organization focused on finding a cure for T1D. Breakthrough T1D provides the fund with access to extensive research, clinical, regulatory, and medical affairs network to support portfolio companies.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Patient-organization-led venture philanthropy that has co-funded and co-invested in myeloma biotech programs alongside venture capital. Same disease-focused donor-funded impact-investment model.

TypeDirect peer
Description

Patient-org-adjacent funder that has grown a venture-style impact program (e.g., the Cancer Research Institute Technology Impact Fund) backing biotech companies in immuno-oncology. Same template as T1D Fund applied to a different disease area.

TypeEmerging player
Description

Publicly listed R&D and venture entity that founds and incubates biotech companies targeting immunology, metabolic, and CNS indications — model-comparable to T1D Fund's catalytic company-creation approach, though PureTech is profit-driven rather than donor-funded.

TypeDirect peer
Description

UK-based medical research charity that has built a venture arm (LifeArc Ventures) making equity investments in early-stage biotech. Notable structural peer because it sits inside a charitable parent and reinvests returns into translational science.

TypeBroad incumbent
Description

Major healthcare-focused private foundation and a foundational partner of T1D Fund itself. Comparable as a large-scale philanthropic funder backing disease-specific translational research and venture philanthropy, though operating with grants more than equity.

TypeDirect peer
Description

Direct disease-focused venture philanthropy fund that makes equity and convert investments in biotech pursuing disease-modifying Alzheimer's therapies. Identical structure: donor-funded impact fund with an experienced investment team and scientific network.

TypeDirect peer
Description

Operates a venture philanthropy program (CFF Therapeutics Lab) that has made equity-like investments in CF-focused biotech for decades. Direct comparable as a disease-focused impact-investment vehicle incubated by a patient organization.

TypeEmerging player
Description

Academic- and foundation-backed drug-discovery accelerator that funds and provides non-dilutive capital plus venture-style support to physician-scientist spinouts. Overlapping model (Harrington scholars + investment vehicle) but more academic and less equity-driven than T1D Fund.

TypeDirect peer
Description

Patient-organization-led venture philanthropy fund accelerating disease-modifying Parkinson's therapeutics. Highly comparable model in mission alignment, donor-funded investing, and emphasis on de-risking translational academic science.

TypeBroad incumbent
Description

Boston-based biotech crossover and venture investor whose TechAtlas division focuses on company creation and disease-area theses. Comparable as a Boston-based specialist biotech investor that co-invests with biopharma alongside T1D Fund.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment54 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

JDRF T1D Fund

Venture Philanthropy / Impact Investment Fundt1dfund.org

The T1D Fund is a Boston-based venture philanthropy fund (founded 2016) that makes equity investments in early-stage biotech companies developing disease-modifying therapies and cures for Type 1 Diabetes, co-investing with VCs and biopharma as a wholly owned subsidiary of Breakthrough T1D.

What JDRF T1D Fund does

The T1D Fund (legally "The T1D Fund: A Breakthrough T1D Venture, LLC") is a Boston-based venture impact fund founded in 2016 as the first scaled venture vehicle exclusively devoted to accelerating treatments, prevention, and cures for Type 1 Diabetes. It operates as a wholly owned not-for-profit subsidiary of Breakthrough T1D (formerly JDRF), a 501(c)(3) organization, and is governed by an independent Investment Committee. The fund makes equity investments in early-stage biotech companies pursuing disease-modifying therapies and curative approaches, co-investing alongside venture capital firms and biopharmaceutical companies across autoimmune and regeneration, cell replacement, and metabolic control modalities. Notable portfolio companies include Sana Biotechnology, Century Therapeutics, Aspect Biosystems, Sonoma Biotherapeutics, DiogenX, Zucara Therapeutics, and Zag Bio, among 25+ companies invested since inception.

The fund's business model is impact-driven and evergreen: capital is sourced through charitable contributions from donors, family foundations, and Breakthrough T1D itself (including a recently announced $150+ million capital raise campaign), and 100% of investment returns are reinvested into new T1D investments rather than distributed. With $250M+ in assets under management, the fund deploys catalytic capital to de-risk programs and create a flywheel effect that attracts additional investors to the T1D space, while providing portfolio companies with access to Breakthrough T1D's research, clinical, regulatory, and medical affairs networks. The fund is based at 50 Milk Street, 16th Floor, Boston, MA 02109, and is supported by an 11-50 person team led by CEO Elizabeth Mily alongside Managing Directors Sylvia Tobé and Lucio Iannone, with recent senior additions including Head of Strategy & Industry Engagement Daniel McNamara and strategic consultant Teresa Foy, Ph.D.

JDRF T1D Fund firmographics

Firmographics
Name
JDRF T1D Fund
Legal name
The T1D Fund: A Breakthrough T1D Venture, LLC
Website
https://t1dfund.org
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
The T1D Fund is a Boston-based venture philanthropy fund (founded 2016) that makes equity investments in early-stage biotech companies developing disease-modifying therapies and cures for Type 1 Diabetes, co-investing with VCs and biopharma as a wholly owned subsidiary of Breakthrough T1D.
Ownership category
akta.pro rank

JDRF T1D Fund industry classification

Industry
Product category
Venture Philanthropy / Impact Investment Fund
NAICS
Open-End Investment Funds (525910)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAJAN
SDG / Thematic Sustainable Investment Funds
Financial & Insurance/Private Equity & Venture Capital/Impact / ESG & Sustainable Investment Funds
SECONDARYBPAGALAA
Impact Investing & Social Finance (Funds, CDFIs, Microfinance)
Business & Public Services/Nonprofit, NGO & Social Services/Social Enterprises & Impact Organizations

Keywords

  • Venture philanthropy fund
  • Biotech impact investing
  • Healthcare venture capital
  • Therapeutics equity investment
  • Clinical-stage biotech funding

Where JDRF T1D Fund is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

JDRF T1D Fund business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

  1. Impact Investment Returns: As an evergreen impact investment fund, the T1D Fund makes equity investments in biotech companies pursuing T1D treatments and cures. All returns from investments are reinvested into new investments, creating a continuous cycle of progress that fuels foundational research and accelerates program development.
  2. Charitable Contributions: Funded through charitable contributions from donors and from Breakthrough T1D itself. As a wholly owned subsidiary of Breakthrough T1D, a 501(c)(3) organization, all donor contributions raised for the Fund are recorded as charitable donations where donors receive tax benefits.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

JDRF T1D Fund product offering

Product offering

Core offering

The JDRF T1D Fund is a venture impact fund that makes equity investments in early- and clinical-stage biotech companies developing treatments and cures for Type 1 Diabetes. The fund, a wholly owned subsidiary of Breakthrough T1D (formerly JDRF), manages $250M+ in committed capital across 20+ active portfolio companies and reinvests 100% of investment returns back into the T1D mission. It also operates a co-investment platform that enables accredited investors and biopharma partners to participate alongside the fund in T1D financings.

Product overview

The T1D Fund operates as a single venture impact fund platform focused on catalyzing treatments, prevention, and cures for type 1 diabetes. The fund makes equity investments in early-stage biotech companies through its co-investment platform, supporting companies across immunotherapy, beta cell therapy, metabolic control, and improving lives approaches. With $250M+ in assets under management and 20+ active portfolio companies (including Aera Therapeutics, Adaxion Therapeutics, AltruBio, Aspect Biosystems, Bigfoot Biomedical, Biolinq, Century Therapeutics, COUR Pharmaceuticals, DiogenX, GentiBio, Immunocore, Inversago Pharma, Jaguar Gene Therapy, Kriya Therapeutics, Mozart Therapeutics, Sana Biotechnology, Semma Therapeutics, Sonoma Biotherapeutics, ZagBio, Zucara Therapeutics, and others), the fund provides investment capital alongside strategic support, leveraging the network and expertise of Breakthrough T1D. All returns are reinvested into the fund to fuel continued progress in T1D therapeutic development.

Differentiator

Problem solved

Functional benefit

Products and services

  • JDRF T1D Fund Venture Impact Fund Equity investment fund making venture-stage investments into early- and clinical-stage biotech companies developing disease-modifying, curative, prevention, beta cell replacement, and diagnostic therapies for Type 1 Diabetes. Targeted at founders and management teams of T1D-focused biotech companies.
  • T1D Co-Investment Platform Syndication platform that allows accredited investors, family offices, VC firms, and biopharma strategic partners to participate alongside the JDRF T1D Fund in portfolio company financings through a donor-advised fund (ImpactAssets) structure with preferred-return economics.

Companies that use JDRF T1D Fund

Customer profile

Segments1 record

Ideal customer profiles2 records

JDRF T1D Fund technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

JDRF T1D Fund partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Breakthrough T1DcoreStrategic or Co-development PartnerThe T1D Fund is a wholly owned subsidiary of Breakthrough T1D (formerly JDRF), the leading global organization focused on finding a cure for T1D. Breakthrough T1D provides the fund with access to extensive research, clinical, regulatory, and medical affairs network to support portfolio companies.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

JDRF T1D Fund competitors and assessment

Company assessment

Direct peers

  • Multiple Myeloma Research Foundation: Patient-organization-led venture philanthropy that has co-funded and co-invested in myeloma biotech programs alongside venture capital. Same disease-focused donor-funded impact-investment model.
  • Cancer Research Institute: Patient-org-adjacent funder that has grown a venture-style impact program (e.g., the Cancer Research Institute Technology Impact Fund) backing biotech companies in immuno-oncology. Same template as T1D Fund applied to a different disease area.
  • LifeArc: UK-based medical research charity that has built a venture arm (LifeArc Ventures) making equity investments in early-stage biotech. Notable structural peer because it sits inside a charitable parent and reinvests returns into translational science.
  • Alzheimer's Drug Discovery Foundation: Direct disease-focused venture philanthropy fund that makes equity and convert investments in biotech pursuing disease-modifying Alzheimer's therapies. Identical structure: donor-funded impact fund with an experienced investment team and scientific network.
  • Cystic Fibrosis Foundation: Operates a venture philanthropy program (CFF Therapeutics Lab) that has made equity-like investments in CF-focused biotech for decades. Direct comparable as a disease-focused impact-investment vehicle incubated by a patient organization.
  • Michael J. Fox Foundation for Parkinson's Research: Patient-organization-led venture philanthropy fund accelerating disease-modifying Parkinson's therapeutics. Highly comparable model in mission alignment, donor-funded investing, and emphasis on de-risking translational academic science.

Emerging players

  • PureTech Health: Publicly listed R&D and venture entity that founds and incubates biotech companies targeting immunology, metabolic, and CNS indications — model-comparable to T1D Fund's catalytic company-creation approach, though PureTech is profit-driven rather than donor-funded.
  • Harrington Discovery Institute: Academic- and foundation-backed drug-discovery accelerator that funds and provides non-dilutive capital plus venture-style support to physician-scientist spinouts. Overlapping model (Harrington scholars + investment vehicle) but more academic and less equity-driven than T1D Fund.

Broad incumbents

  • The Leona M. and Harry B. Helmsley Charitable Trust: Major healthcare-focused private foundation and a foundational partner of T1D Fund itself. Comparable as a large-scale philanthropic funder backing disease-specific translational research and venture philanthropy, though operating with grants more than equity.
  • RA Capital Management: Boston-based biotech crossover and venture investor whose TechAtlas division focuses on company creation and disease-area theses. Comparable as a Boston-based specialist biotech investor that co-invests with biopharma alongside T1D Fund.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

JDRF T1D Fund social profiles

Digital presence

JDRF T1D Fund financial estimates

Financial estimate

Revenue estimate

Valuation estimate

JDRF T1D Fund leadership team

Management profile

Number of profiles

Profiles11 records

JDRF T1D Fund funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

JDRF T1D Fund M&A and investment

M&A and investment

M&A

Investments54 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about JDRF T1D Fund

What does JDRF T1D Fund do?

The JDRF T1D Fund is a venture impact fund that makes equity investments in early- and clinical-stage biotech companies developing treatments and cures for Type 1 Diabetes. The fund, a wholly owned subsidiary of Breakthrough T1D (formerly JDRF), manages $250M+ in committed capital across 20+ active portfolio companies and reinvests 100% of investment returns back into the T1D mission. It also operates a co-investment platform that enables accredited investors and biopharma partners to participate alongside the fund in T1D financings.

Is JDRF T1D Fund a public or private company?

JDRF T1D Fund is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was JDRF T1D Fund founded?

JDRF T1D Fund was founded in 2016. It employs 11 to 50 people.

Where is JDRF T1D Fund based?

JDRF T1D Fund is headquartered in Boston, United States, in the North America region.

How does JDRF T1D Fund make money?

Two revenue lines are on record. Impact Investment Returns are the primary driver. The others are charitable Contributions.

Who are JDRF T1D Fund's main competitors?

Direct peers on record are Multiple Myeloma Research Foundation, Cancer Research Institute, LifeArc, Alzheimer's Drug Discovery Foundation, Cystic Fibrosis Foundation and Michael J. Fox Foundation for Parkinson's Research. Emerging players are PureTech Health and Harrington Discovery Institute. Broad incumbents are The Leona M. and Harry B. Helmsley Charitable Trust and RA Capital Management.

Does JDRF T1D Fund have an API?

No public API is recorded for JDRF T1D Fund.

What industry is JDRF T1D Fund in?

JDRF T1D Fund's product category is Venture Philanthropy / Impact Investment Fund. Its primary akta.pro industry code is FSANAJAN, SDG / Thematic Sustainable Investment Funds, with a secondary code of BPAGALAA, Impact Investing & Social Finance (Funds, CDFIs, Microfinance). Its NAICS code is 525910 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswirevTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D FundvTv Therapeutics closed a $51 million private placement with institutional investors, including Samsara and the JDRF T1D Fund, issuing 464,377 shares and pre-funded warrants for 3,853,997 shares. The company will use proceeds to fund the first Phase 3 study of cadisegliatin, expected to start in mid-2024.GlobeNewswirevTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D FundvTv Therapeutics closed a $51 million private placement with institutional investors, including Samsara and the JDRF T1D Fund, issuing 464,377 shares and pre-funded warrants for 3,853,997 shares. The company will use the proceeds to fund the first Phase 3 study of cadisegliatin, expected to start in mid-2024.VtvtherapeuticsvTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D FundvTv Therapeutics closed a $51 million private placement from healthcare-focused institutional investors, including Samsara BioCapital and the JDRF T1D Fund. The company concurrently reduced its Board of Directors from nine to seven members, with three seats designated by the new investors. Proceeds will fully fund the first Phase 3 study of cadisegliatin for type 1 diabetes, expected to initiate in mid-2024.BioSpacevTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D FundvTv Therapeutics closed a $51 million private placement of common stock and pre-funded warrants to healthcare-focused institutional investors, including Samsara BioCapital and the JDRF T1D Fund. The company concurrently reduced its Board of Directors from nine to seven members, with three seats designated by the new investors. Proceeds from the financing will fully fund the first Phase 3 study of cadisegliatin, expected to initiate in mid-2024.SecEX-99.1vTv Therapeutics has closed a $51 million private placement to support the Phase 3 study of cadisegliatin as a therapy for type 1 diabetes (T1D). The funding involves the issuance of shares and pre-funded warrants to healthcare-focused institutional investors, including Samsara BioCapital and the JDRF T1D Fund. The initiative aims to further advance the development of cadisegliatin, with the potential for significant benefits for individuals living with T1D.JaguargenetherapyJaguar Gene Therapy Announces Samsung and JDRF T1D Fund as New InvestorsJaguar Gene Therapy announced that Samsung Ventures and the JDRF T1D Fund have invested in the company to support its gene therapy development. The funding will be used to expand Chemistry, Manufacturing and Controls (CMC) capabilities and advance IND-enabling activities for preclinical programs targeting Type 1 galactosemia, autism spectrum disorder, and Type 1 diabetes.Business Wire BlogJaguar Gene Therapy Announces Samsung and JDRF T1D Fund as New InvestorsJaguar Gene Therapy announced that Samsung Ventures and the JDRF T1D Fund have invested in the company to support its preclinical pipeline of gene therapies. The funding will be used to expand CMC capabilities and advance IND-enabling activities for programs targeting Type 1 galactosemia, autism spectrum disorder-related disorders, and Type 1 diabetes.ImpactalphaHow disease-focused venture philanthropy can accelerate curesThe JDRF T1D Fund, a venture philanthropy fund, has invested over $375 million in T1D programs since its launch. It aims to catalyze venture capital in the disease, which had been largely ignored by investors. The fund has demonstrated that mission-driven investment can de-risk a disease area and draw capital to the field.Pulse 2.0Harvard-Launched Startup i2O Raises $4 Million To Develop Biological Oral Drugsi2O Therapeutics, a Harvard-launched biotech, raised $4 million in seed funding led by Sanofi Ventures and JDRF T1D Fund. The company develops a platform for oral delivery of injectable biological drugs, with initial focus on GLP-1 analogs. The financing will support team expansion and R&D.